MRNAC Stock Price and Chart — BCBA:MRNAC

Overview

Key facts today

Moderna's Q2 revenue was $142 million, down 41% year-over-year, with a net loss of $825 million. The 2025 revenue forecast was cut to $1.5-$2.2 billion, causing shares to drop 7.1%.

The U.K. Court of Appeal upheld Moderna's EP'949 patent, confirming Pfizer and BioNTech's Comirnaty vaccine infringed it. This ruling entitles Moderna to damages for sales post-March 2022.

Moderna is working on new mRNA products, including a COVID-flu vaccine, due to falling COVID vaccine sales and slow RSV rollout. They are consulting with regulators on approval data.

Analyze the impact Analyze the impact

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as MRNAC.